Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | MANIFEST: CPI-0610 + ruxolitinib in advanced myelofibrosis patients

Srdan Verstovsek, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, updates us on the Phase II MANIFEST study (NCT02158858), evaluating the addition of CPI-0610, a bromodomain and extraterminal domain protein inhibitor, to ruxolitinib in advanced myelofibrosis patients with suboptimal responses. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).